Atea Pharmaceuticals offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines the advantages of current first-line HCV therapies—single pill ...
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback